SGLT1-sparing oral SGLT2 inhibitor prodrug

launched in India for diabetes, 100 mg BID

from mouse urine drug metabolite and opt.

Bioorg. Med. Chem., Jan. 22, 2021

Kissei Pharma / Toho University, JP

Remogliflozin-etabonate

The Kissei SGLT2 inhibitor prodrug, remogliflozin etabonate, is an SGLT1-sparing oral drug launched in 2019 in India for the treatment of type 2 diabetes.  Interestingly, the lead for this drug…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: